Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer

doi:10.4251/wjgo.v10.i1.31

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7127)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

400

WORD

209

HTML

3075

Figures (1-3)

269

Tables (1-5)

257

Sum=4210

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1171

Download

1746

Sum=2917

Jan 15, 2018 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jan 15, 2018; 10(1): 31-39
Published online Jan 15, 2018. doi: 10.4251/wjgo.v10.i1.31

Open in New Tab Full Size Figure Download Figure

Figure 1 Study flow diagram.

Open in New Tab Full Size Figure Download Figure

Figure 2 Overall survival of patients with T4bN1-3M0/TxN3bM0 gastric cancer after curative resection according to the patterns of recurrence.

Open in New Tab Full Size Figure Download Figure

Figure 3 Kaplan-Meier curves of disease-free survival (A) and overall survival (B) for T4bN1-3M0/TxN3bM0 gastric cancer patients after curative gastrectomy according to the duration of adjuvant chemotherapy. P value by log-rank test. A: Disease-free survival (DFS): 23.2 mo vs 9.9 mo, P = 0.0001; B: Overall survival: 40.2 mo vs 21.6 mo, P = 0.001. CT: Chemotherapy.

Citation: Wang QW, Zhang XT, Lu M, Shen L. Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World J Gastrointest Oncol 2018; 10(1): 31-39
URL: https://www.wjgnet.com/1948-5204/full/v10/i1/31.htm
DOI: https://dx.doi.org/10.4251/wjgo.v10.i1.31